Connect & Collaborate Presenters

AUTM Annual Meeting

Lineup of Presenters

Rubén Flores-Saaib
Academic Innovations and Partnerships Lead
​General Inception


Rubén is a native of Nayarit, México and is the Academic Innovations and Partnerships Lead at General Inception. Throughout his career, Rubén has led and developed academic and corporate teams working on commercialization and partnering programs in life sciences, diagnostics, therapeutics, artificial intelligence, materials, and software. Rubén is also a co-founder, and past President, of the San Diego Innovation Council, a coalition of academic research institutes working together to elevate the profile of the San Diego innovation ecosystem to the world.
 
Rubén received his Ph.D. from UCLA’s Department of Chemistry and Biochemistry. He began his career as a Scientist at BD Biosciences Pharmigen, later moved to Biosite (now Abbott) as a Clinical Scientist and Agreements Manager, and then joined Chemicon (acquired by Serologicals) to lead the Luminex Multiplex and Diagnostics teams. Rubén was a founding Director of the Scientific Collaborations and Business Development group started by Millipore following the acquisition of Serologicals and continued in that role when Merck KGaA acquired Millipore. Ruben capped his career in the corporate world as Vice President of Marketing and Product Development at Genway Biotech.

Rubén’s 10-year in academic technology transfer began as Vice President for Business Development at LA BioMed (now the Lundquist Institute), continued as Director at UC San Diego and most recently as Associate Director of Licensing at the University of Southern California.

David Lough 
Director of Academic Partnerships, Global Strategy & Corporate Development
Chiesi Group

In his role at Chiesi, David Lough focused on building and developing academic relationships with researchers from leading universities, academic medical centers and research institutes to develop breakthrough therapies and technologies for respiratory diseases, neonatal care and rare diseases. David is responsible for search and evaluation for new therapeutic candidates, and the negotiation of academic transactions such as sponsored research agreements and license agreements. 

Prior to joining Chiesi, David was Director of Life Sciences Business Development in the Office of Technology Development at Boston University. 

David earned both his Bachelor of Science in Evironmental Chemistry and Ph.D. in Bioorganic Chemistry from Edinburgh University. He also earned a Graduate Certificate in Intellectual Property from Northeastern University. 

Matthew Seavey
VP Research and Technology Acquisition
NightHawk Biosciences, Inc.


As Vice President of Research and Technology Acquisition, Matthew Seavey, holds over a 15 years in drug development experience.  Matt holds a BS in Microbiology, MS and PhD in Immunology and an MBA in Business Development.  Originally trained as an immunologist and an expert in early drug development, Matt has been involved in the development of different drug modalities (biologics, small molecules, cellular therapeutics, vaccines) across multiple therapeutic areas including, GI, infectious diseases, immuno-oncology, respiratory, inflammation and cardio-metabolics.  Matt has held former positions as Drug Discovery Team Leader at Cephalon, Global Pharmacology Project Leader at Teva Pharmaceuticals, Oncology Program Director at United Therapeutics.  Matt is a co-inventor on several patents and has contributed to the intellectual property base of Advaxis and founding of Oncoceutics.



Annual Meeting Sponsors

AstraZeneca
Amster, Rothstein & Ebenstein LLP
Wellspring
KPPB
Osage University Partners
PhRMA
Casimir Jones, SC
Michael Best & Friedrich
Cayuse
NIIMBL
Boehringer Ingelheim Pharmaceuticals Inc.
Nixon Peabody
Parker Highlander PLLC
LevelSet Capital
Merck
Marshall Gerstein
InfoEd
Blank Rome LLP
KISSPlatform Europe BV
Novartis
LockeLord
Elsevier
Quarles & Brady LLP
Computer Packages, Inc.
Boehringer Ingelheim
Schwegman Lundberg & Woessner
NYU Langone
Berggren
RWS
Fox Rothschild LLP